Cyclacel Pharmaceuticals (NASDAQ:CYCC) will be announcing its Q3 earnings results after the market closes on Monday, November 12th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.04). On average, analysts expect Cyclacel Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
NASDAQ CYCC opened at $1.25 on Friday. Cyclacel Pharmaceuticals has a fifty-two week low of $1.14 and a fifty-two week high of $2.25.
Several equities analysts have recently commented on the company. Zacks Investment Research raised Cyclacel Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 17th. ValuEngine raised Cyclacel Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Roth Capital set a $8.00 price target on Cyclacel Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, October 4th. LADENBURG THALM/SH SH assumed coverage on Cyclacel Pharmaceuticals in a research note on Friday, September 7th. They issued a “buy” rating and a $6.25 price target on the stock. Finally, HC Wainwright set a $7.00 price target on Cyclacel Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 10th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $5.75.
TRADEMARK VIOLATION WARNING: “Cyclacel Pharmaceuticals (CYCC) to Release Quarterly Earnings on Monday” was reported by Macon Daily and is the property of of Macon Daily. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://macondaily.com/2018/11/11/cyclacel-pharmaceuticals-cycc-to-release-quarterly-earnings-on-monday.html.
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.
Recommended Story: Consumer behavior in bull markets
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.